This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FUSN Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Fusion Pharmaceuticals Stock (NASDAQ:FUSN) 30 days 90 days 365 days Advanced Chart Get Fusion Pharmaceuticals alerts:Sign Up Key Stats Today's Range$21.55▼$21.5550-Day Range$21.38▼$21.5552-Week Range$2.31▼$21.60VolumeN/AAverage Volume1.69 million shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada. Read More Receive FUSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address FUSN Stock News HeadlinesFusion Pharma Stock Price HistoryMay 24, 2025 | investing.comAstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer PipelineFebruary 20, 2025 | investopedia.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 2 at 2:00 AM | Banyan Hill Publishing (Ad)Fusion Finance Ltd (FUSN)November 4, 2024 | investing.comJapan start-up aims to launch world's first steady-state fusion reactor in 2034August 31, 2024 | msn.comFusion Pharma (FUSN) Earnings Dates & ReportsAugust 7, 2024 | investing.comAcquisition of Fusion Pharmaceuticals CompletedJune 4, 2024 | prnewswire.comFusion Pharmaceuticals Receives Final Court Order Approving ArrangementMay 31, 2024 | prnewswire.comSee More Headlines FUSN Stock Analysis - Frequently Asked Questions How were Fusion Pharmaceuticals' earnings last quarter? Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its earnings results on Tuesday, November, 9th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.13. The company had revenue of $0.33 million for the quarter. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.74% and a negative net margin of 4,136.55%. When did Fusion Pharmaceuticals IPO? Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Fusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW). Company Calendar Last Earnings11/09/2021Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FUSN CIK1805890 Webfusionpharma.com Phone289-799-0891FaxN/AEmployees101Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$94.90 million Net Margins-4,136.55% Pretax Margin-5,084.07% Return on Equity-48.74% Return on Assets-36.87% Debt Debt-to-Equity Ratio0.21 Current Ratio10.64 Quick Ratio10.64 Sales & Book Value Annual Sales$2.07 million Price / Sales885.53 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book7.02Miscellaneous Outstanding Shares85,060,000Free Float78,468,000Market Cap$1.83 billion OptionableOptionable Beta-0.69 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:FUSN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.